**S1 Table:** Summary of findings.

|  |
| --- |
| **Y90-TARE versus standard treatment in patients with non-surgical hepatocellular carcinoma (HCC)**Population: Patients with non-surgical HCCSetting: oncologic treatment centers in North America, Pacific-Asia, Turkey and EuropeIntervention: Y90-TARE treatment strategiesComparison: Standard treatment (TACE and sorafenib) |
| Outcomes | Illustrative comparative risk  | Effect estimate(95% CI) | Number of participants  | Quality of the evidence (GRADE) | Comments |
| **Y90-TARE** | **Standard treatmenta** |  |  |  |  |
| **Overall survival** | Estimated median in months |  HR=0.99(0.81-1.21) | 1380 in 6 studies | Low | … |
| 15.5 | 15 |
| **Progression-free survival**  | Estimated median in months | HR=0.96(0.83-1.11) | 843 in 3 studies | Very low | … |
| 21.5 | 20.5 |
| **Time to progression** | Estimated median in months | HR=0.49 (0.20-1.21) | 497 in 4 studies | Very low | … |
| 19.5 | 9.5 |
| **Disease control rate** | Estimated proportions  | RR=0.95 (0.77-1.16) | 893 in 5 studies | Very low | … |
| 491/1000 | 562/1000 |
| **Grade** $\geq $**3 adverse events** | Estimated proportions | RR=0.64 (0.45-0.92) | 1245 in 7 studies | Low | This effect was associated with the use of sorafenib as a comparator, the absence of an active co-intervention and a balanced proportion of the different BCLC stages. |
| 284/1000 | 438/1000 |
| **Incidence of gastro-intestinal ulcers** | Estimated proportions | RR=2.73(0.70 -10.59) | 1105 in 4 studies | Very low | … |
| 13/1000 | 3/1000 |

aEstimated median survival for standard treatment for OS, progression-free survival and time to progression are assumed median survival which we calculated from weighted median survival from the trials.